ICYMI, some of the content featured this week includes a new podcast episode, a new FDA approval for actinic keratosis, examining quality of care for atopic dermatitis, plus more.
In case you missed it, some of this week’s featured content includes a new podcast episode about health care PPE dermatoses during COVID-19. Also, articles on melasma treatments, quality of care for atopic dermatitis, implementing PR into your marketing plan, a new U.S. Food and Drug Administration (FDA) approval for actinic keratosis, long-term safety and drug survival of oral systemics for psoriasis, plus more.
For 2020, trending topics can be summed up in one word: COVID-19. But, even during a pandemic, dermatologists and the medical community at large continued to research novel therapies and seek new solutions for providing the best possible patient care. Here, Dermatology Times tracks the most compelling topics of an unprecedented year.
This week’s edition of The Mainstream Patient features stories on “slugging”, dermarolling, physical versus chemical exfoliants, acne scar treatments, plus more.
Todd Petersen, CEO of VitalSkin Dermatology, discusses the last part of your transition journey – ensuring a smooth, successful transition for you, your team and your patients.
Ashley Buehnerkemper, director of marketing at VitalSkin Dermatology, discusses what steps you can take to make public relations an active piece of your practice marketing.
Half of patients are satisfied with their atopic dermatitis treatment and more than half of patients worry about topical steroid side effects, addiction and withdrawal, according to a recent study.
Next-generation therapies explore solutions other than laser treatments, and are less invasive, safer and require less downtime.
Tirbanibulin (Klisyri, Almirall) has been approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of actinic keratosis on the face or scalp.
Since the start of the pandemic, there has been a rise in dermatoses in healthcare workers related to occupational use of personal protective equipment (PPE). Rachel Evers-Meltzer, MD, MPH, discusses her cross-sectional survey investigating what types of dermatoses were most commonly seen in the health care spear and suggests possible treatments.
Highlighting the relationship between long-term safety and drug survival, a recent review may help address physician reluctance in prescribing conventional systemic psoriasis treatments.
A new innovative report identifies gaps and offers solutions for improving quality of care in atopic dermatitis (AD).
A vast majority of patients with atopic dermatitis (AD) are satisfied with dupilumab (Dupixent, Sanofi and Regeneron) treatment, according to research presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress.
Dermatologists should consider assessing melasma patients for increased vascularity and include antivascular treatments to improve outcomes among patients whose lesions have a vascular component.